Narmac,

Will you please provide a link or reference to ZEN-3309 and breast cancer? I don't recall Zenith ever stating that the breast cancer trial  would be with ZEN-3309. I think we were told via news release that it would be with ZEN-3694. ZEN-3694 has been shown to synergize with lots of drugs, including PARP inhibitors and enzalutamide. As for CURATE.AI, management stated at AGM that the first patient was free of charge but that the CURATE.AI folks wanted to charge big bucks to apply its use in subsequent patients. That's my recollection. Check the AGM transcript in the link library. 

BearDownAZ